Top Markets
Coin of the day
MGC Pharmaceuticals Limited MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited

MXC
株式のランク #39836
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established... MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.
株価
$0.27239819
最終同期: 2024-04-29
時価総額
$330.42K
変化(1日)
0.52%
変化(1年)
0.00%
AU
取引 MGC Pharmaceuticals Limited (MXC)

カテゴリー

MGC Pharmaceuticals Limited(MXC)のP/S比率
2026 時点のP/S比率 TTM: 0
MGC Pharmaceuticals Limited の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
MGC Pharmaceuticals Limited の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。